From: Impact of self-reported Gastroesophageal reflux disease in subjects from COPDGene cohort
 | GERD (n = 1,307) | No GERD (n=3,176) | Total (n = 4,483) | P-value |
---|---|---|---|---|
Comorbidities | ||||
Cardiovascular disease** | 21.3 | 14.0 | 16.1 | <0.0001 |
Congestive heart failure | 5.7 | 4.1 | 4.6 | 0.01 |
Hypertension | 55.7 | 45.2 | 48.3 | <0.0001 |
Diabetes mellitus | 13.5 | 11.7 | 12.3 | 0.08 |
Peripheral vascular disease | 4.7 | 2.5 | 3.2 | 0.0001 |
Osteoporosis/Compression fractures | 25.0 | 13.4 | 16.8 | <0.0001 |
Any arthritis | 28.6 | 15.8 | 19.5 | <0.0001 |
Sleep apnea | 22.2 | 13.5 | 16.1 | <0.0001 |
2 or more modifiable risk factors*** | 60.5 | 50.5 | 53.4 | <0.0001 |
Disease impact and health-related quality-of-life | ||||
Six minute walk distance (feet) [mean (s.d.)] | 1,192 (392) | 1,250 (413) | 1,233 (408) | <0.0001 |
BODE [mean (s.d.)] | 2.7 (2.0) | 2.4 (2.1) | 2.5 (2.1) | 0.001 |
MMRC dyspnea score [mean (s.d.)] | 2.2 (1.4) | 1.8 (1.5) | 1.9 (1.5) | <0.0001 |
SGRQ total score [mean (s.d.)] | 41.8 (22.3) | 34.9 (22.9) | 36.9 (22.9) | <0.0001 |
SF-36 PCS | 38.2 (10.4) | 41.4 (11.2) | 40.4 (11.0) | <0.0001 |
SF-36 MCS | 48.0 (13.2) | 49.1 (12.3) | 48.8 (12.6) | 0.07 |
Exacerbation in the year prior to enrollment [mean (s.d.)] | 0.9 (1.3) | 0.6 (1.1) | 0.7 (1.2) | <0.0001 |
Hospitalized exacerbations in the year prior to enrollment (%) | 22.0 | 18.6 | 19.5 | 0.008 |
Frequent exacerbator phenotype [>/=2 exacerbations per annum] (%) | 22.5 | 12.9 | 15.7 | <0.0001 |
Exacerbations per year during follow-up [mean (s.d.)] | 0.9 (1.7) | 0.6 (1.6) | 0.7 (1.6) | <0.0001 |
Frequent exacerbator phenotype during follow-up [>/=2 exacerbations per annum] (%) | 17.9 | 14.7 | 16.9 | <0.0001 |